Van Lanschot Kempen NV (AMS:VLK)

Netherlands flag Netherlands · Delayed Price · Currency is EUR
50.10
-0.10 (-0.20%)
Sep 29, 2025, 3:49 PM CET
-0.20%
Market Cap2.13B
Revenue (ttm)733.80M
Net Income (ttm)126.29M
Shares Out42.37M
EPS (ttm)2.98
PE Ratio16.85
Forward PE15.26
Dividend4.15 (8.27%)
Ex-Dividend DateJun 24, 2025
Volume26,703
Average Volume68,581
Open50.20
Previous Close50.20
Day's Range50.00 - 50.60
52-Week Range38.00 - 59.80
Beta0.86
RSI36.41
Earnings DateFeb 26, 2026

About Van Lanschot Kempen NV

Van Lanschot Kempen NV provides various financial services in the Netherlands, Belgium, and internationally. It operates through four segments: Private Clients Netherlands, Private Clients Belgium, Investment Management Clients, and Investment Banking Clients. The company offers private banking services for entrepreneurs, family businesses, high-net-worth individuals, business professionals and executives, foundations and associations, and affluent individuals; and pension funds for institutional clients. It also provides wealth management serv... [Read more]

Sector Financials
Founded 1737
Employees 2,018
Stock Exchange Euronext Amsterdam
Ticker Symbol VLK
Full Company Profile

Financial Performance

In 2024, Van Lanschot Kempen NV's revenue was 726.04 million, an increase of 8.80% compared to the previous year's 667.35 million. Earnings were 131.86 million, an increase of 11.32%.

Financial Statements

News

Van Lanschot Kempen NV 2025 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Van Lanschot Kempen NV in conjunction with their 2025 Q2 earnings call.

4 weeks ago - Seeking Alpha

Van Lanschot Kempen NV reports 1H results

4 weeks ago - Seeking Alpha

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to add...

2 months ago - Benzinga